Table 2.

Univariate and multivariate analysis of 36-gene signature and usual prognostic factors in relation to disease-free survival

Predictive factorsUnivariate analysisMultivariate analysis
Odds ratio (95% CI)POdds ratio (95% CI)P
A. Training set (132 patients)
    36-gene signature: RF vs R14.61 (6.07-35.19)6.3 × 10−1117.89 (5.62-56.94)1.05 × 10−6
    SBR grade: 1/2 vs 34.60 (1.87-11.27)0.00081.46 (0.37-5.74)0.59
    Tumor size: <20 vs ≥20 mm1.99 (0.86-4.57)0.11
    PR: ≥20 vs <20 fmol/mg3.68 (1.49-9.07)0.0052.73 (0.68-10.91)0.16
    Age: ≥55 vs <55 y1.87 (0.57-6.10)0.31
    ER: ≥20 vs <20 fmol/mg1.07 (0.26-4.51)0.95
    Node status: pN0 vs pN+4.58 (2.03-10.33)0.00013.05 (0.75-12.45)0.12
    NPI: ≤3.4 vs > 3.47.16 (2.33-22.04)0.00013.27 (0.64-16.82)0.16
    Adjuvant!: <20% vs ≥20%4.71 (2.08-10.67)0.00021.22 (0.31-4.76)0.78
B. Validation set (83 patients)
    36-gene signature: RF vs R3.96 (1.56-10.05)0.0043.01 (1.01-9.14)0.05
    SBR grade: 1/2 vs 32.02 (0.76-5.39)0.17
    Tumor size: <20 vs ≥20 mm2.16 (0.83-5.60)0.12
    PR: ≥20 vs <20 fmol/mg2.16 (0.72-6.52)0.18
    Age: ≥55 vs <55 y2.41 (0.62-9.30)0.22
    ER: ≥20 vs < 20 fmol/mg4.65 (0.46-46.69)0.21
    Node status: pN0 vs pN+2.37 (0.92-6.10)0.08
    NPI: ≤3.4 vs >3.45.96 (1.25-28.33)0.0132.27 (0.35-14.35)0.38
    Adjuvant!: <20% vs ≥20%4.90 (1.75-13.69)0.0022.64 (0.78-8.91)0.12
  • NOTE: Univariate and multivariate analyses were done by logistic regression. Multivariate analysis was done using the variables found to be significant in univariate analysis. Significant values are in bold characters.

    Abbreviations: DFS, disease-free survival; RF, relapse-free; R, relapse; NPI, Nottingham prognostic index; 95% CI, 95% confidence interval.